Dynavax Technologies Corp... (DVAX)

Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its sup...

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communicati...

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago.

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine inst...

Goldman Sachs downgraded Dynavax Technologies Corporation DVAX reflecting updated views and recent competitive dynamics for vaccines.

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 93.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...

Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).